News

Media Coverage

Media coverage of Reforgene Medicine.

Home/ News/ Media Coverage
Hainan TV: first successful gene editing treatment of thalassemia in Hainan
2025.11.10

Hainan TV: first successful gene editing treatment of thalassemia in Hainan

Hainan Television reported the first successful gene editing treatment of thalassemia in Hainan, highlighting Reforgene's innovation.

China Association of Social Workers launches public assistance program for thalassemia
2023.11.29

China Association of Social Workers launches public assistance program for thalassemia

A public assistance program for thalassemia was officially launched by the China Association of Social Workers.

2023.11.06

Guangzhou TV: innovative medicine renews hope as Reforgene's gene editing drug achieves clinical cure in a girl with severe thalassemia

Guangzhou Television reported that Reforgene's gene editing drug achieved clinical cure in a girl with severe thalassemia.

Repairing genes with an approved 'gene scissors': a girl with severe thalassemia achieves clinical cure
2023.08.01

Repairing genes with an approved 'gene scissors': a girl with severe thalassemia achieves clinical cure

Using an approved gene editing approach, a girl with severe thalassemia achieved clinical cure.

AI plus gene editing: how this company successfully treated adult thalassemia
2022.05.28

AI plus gene editing: how this company successfully treated adult thalassemia

A media feature on how Reforgene combines AI and gene editing and has successfully treated adult thalassemia.

Breakthrough: China's gene editing technology successfully treats adult severe thalassemia
2022.03.28

Breakthrough: China's gene editing technology successfully treats adult severe thalassemia

Media reports highlight a breakthrough in which China's gene editing technology successfully treated adult patients with severe thalassemia.

Reforgene achieves a new breakthrough in treating severe beta-thalassemia with a novel global target
2021.12.30

Reforgene achieves a new breakthrough in treating severe beta-thalassemia with a novel global target

Reforgene reported a new breakthrough in treating severe beta-thalassemia through a novel global target.

NMPA CDE issues guidance on common formats for manufacturing processes and quality standards of Chinese medicines, chemicals and biological products
2021.07.20

NMPA CDE issues guidance on common formats for manufacturing processes and quality standards of Chinese medicines, chemicals and biological products

China's CDE issued guidance on common formats for manufacturing processes and quality standards across drug categories.

View all coverage (24 items)
2020.12.23

EU approves autologous hematopoietic stem cell gene therapy for metachromatic leukodystrophy

2020.11.19

Interview: gene editing technology is opening a new class of medicines

2020.10.09

CDE seeks comments on technical guidance for pharmaceutical research and evaluation of gene transduction and modification systems

2020.10.09

Two gene editing scientists win the 2020 Nobel Prize in Chemistry

2020.08.31

Base editing delivery innovation achieves proof of concept for lipid-lowering gene therapy and eye disease treatment

2020.06.27

Nature reports precise PTB gene regulation that eliminates Parkinson's symptoms

2020.06.03

Exosome-mediated intercellular delivery of CRISPR/Cas9 targeting the hepatitis B virus genome

2020.03.23

Crossing the blood-brain barrier: a novel delivery technology for Parkinson's gene therapy

2020.03.23

Two gene therapies can cure rare genetic diseases

2020.02.05

Nature Medicine: gene therapy for Duchenne muscular dystrophy

2020.02.05

UC scientists develop CRISPR-engineered stem cell models

2019.11.09

First in the U.S.: CRISPR gene editing applied to cancer treatment

2019.10.16

PNAS: a new SaCas9-HF variant improves CRISPR-Cas9 gene editing precision

2019.09.27

A new CRISPR tool explores 90% of the gene editing landscape

2019.09.27

Cell: a revolutionary Cas13d and the rise of new gene editing tools

2019.09.15

Improved CRISPR successfully targets triple-negative breast cancer with up to 77% efficacy

2019.09.15

Comparing international regulation of cell and gene therapy products and implications for China

2019.09.14

Personalized neoantigen cancer vaccines: are more targets always better?

2019.09.12

Gene editing powers intelligent nucleic acid hydrogels: latest results from Shanghai Jiao Tong University School of Medicine

2019.09.05

CRISPR-Cas9 gene editing in three major tumor immunotherapy approaches

2019.04.09

Unprecedented: Chinese scientists use gene therapy to let congenitally deaf mice hear whispers

2019.03.20

NEJM: world's first successful gene therapy clinical trial for sickle cell disease

2019.02.13

Nature: unraveling the lethal cytokine storm behind CAR-T toxicity and a potential preventive role for existing hypertension drugs

2019.02.11

Nature sub-journal: Sun Yat-sen University discovers the first method to detect ABE genome-wide off-target effects